ARTHRIAID

Main information

  • Trade name:
  • ARTHRIAID Film Coated Tablet 1500 Milligram
  • Dosage:
  • 1500 Milligram
  • Pharmaceutical form:
  • Film Coated Tablet
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ARTHRIAID Film Coated Tablet 1500 Milligram
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA1521/001/003
  • Authorization date:
  • 22-07-2011
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

Arthriaid1500mgFilm-CoatedTablets

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachfilm-coatedtabletcontains1884mgglucosaminesulfatesodiumchlorideequivalentto1500mgglucosamine

sulfate.

Excipients:

Eachtabletcontains151.8mg(6.6mmol)ofsodium.

Lactosemonohydrate6.0mg

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Film-coatedtablet

Off-white,oblong-shapedfilm-coatedtablet

4CLINICALPARTICULARS

4.1TherapeuticIndications

Arthriaidtabletsareindicatedforthetreatmentofosteoarthritisoflowtomoderatedegree.

4.2Posologyandmethodofadministration

Administration:

Arthriaidtabletsshouldbeswallowedwhole.

Adultsandtheelderly:

OneArthriaidtabletshouldbetakenoncedaily.

Efficacyofglucosaminehasbeendemonstratedforperiodsofuptothreemonths,witharesidualeffectevidentfortwo

monthsafterdrugwithdrawal.Thesafetyandefficacyoftheproductwerealsoconfirmedinpivotalclinicaltrialsfor

treatmentuptothreeyears.Continuoustreatmentbeyond3yearscannotberecommendedasthesafetyhasnotbeen

establishedbeyondthisperiod.

Children:

Safetyandefficacyhasnotbeenestablishedinchildren,therefore,Arthriaidtabletsshouldnotbeusedinpersonsunder

theageof18years.

Impairedrenaland/orliverfunction

Inpatientswithimpairedrenaland/orliverfunctionnodoserecommendationscanbegiven,sincenostudieshavebeen

performed.

4.3Contraindications

Knownsensitivitytoglucosamine(oranyofitsderivatives),sulfatesoranyoftheotheringredientsinArthriaidtablets

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 26/07/2011 CRN 2055044 page number: 1

4.4Specialwarningsandprecautionsforuse

Warnings

Arthriaidtabletscontainlactosemonohydrate,patientswithrarehereditaryproblemsofgalactoseintolerance,theLapp

lactasedeficiencyorglucose-galactosemalabsorptionshouldnottakethismedicine.

Thismedicinalproductcontains151.8mgsodiumperdoseequivalentto6.6mmol.Tobetakenintoconsiderationby

patientsonacontrolledsodiumdiet.

Precautions

Sinceglucosamineisextractedfromshellfish,personswhoareallergictoshellfishshouldexercisecautionintheuseof

theproduct,althoughtherehavebeennoreportedcasesoftheseallergiestoglucosamine.

Cautionisadvisedintreatmentofpatientswithimpairedglucosetolerance.Closermonitoringofbloodsugarlevels

maybenecessaryindiabeticsatthebeginningoftreatment.

Inpatientswithaknownriskfactorforcardiovasculardisease,monitoringofthebloodlipidlevelsisrecommended

sincehypercholesterolemiahasbeenobservedinafewpatientstreatedwithglucosamine.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Noformaldruginteractionstudieshavebeenperformed,however,thephysico-chemicalandpharmacokinetic

propertiesofglucosaminesulfatesuggestalowpotentialforinteractions.Thecompounddoesnotcompetefor

absorptionmechanismsand,afterabsorption,doesnotbindtoplasmaprotein,whileitsmetabolicfateasan

endogenoussubstanceincorporatedinproteoglycansordegradedindependentlyofthecytochromeenzymesystem,is

unlikelytogiverisetodruginteractions.

However,anincreasedeffectofwarfarinduringconcomitanttreatmentwithglucosaminehasbeenreportedinpost-

marketingexperience.Therefore,morefrequentmeasurementofthewarfarineffectmaybeconsidered.

Closemonitoringofbloodsugarlevelsisrecommendedfordiabeticsonhypoglycaemicagents.

Theoraladministrationofgluclosaminesulfate,canenhancethegastrointestinalabsorptionoftetracyclines.

4.6Fertility,pregnancyandlactation

Inanimalstudies,nounfavourableeffectsonreproductivefunctionoronlactationhavebeendemonstrated.Inthe

absenceofsuchstudiesinhumans,theuseofglucosaminesulfateduringpregnancyandlactationshouldbelimitedto

caseswherethebenefitsoutweighthepotentialrisks.Administrationduringthefirst3monthsofpregnancyshouldbe

avoided.

4.7Effectsonabilitytodriveandusemachines

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 26/07/2011 CRN 2055044 page number: 2

4.8Undesirableeffects

Themostcommonadversereactionsassociatedwithtreatmentwithglucosaminearenausea,abdominalpain,

indigestion,constipationanddiarrhoea.Inaddition,headache,tiredness,rash,itching,andflushinghavebeen

reported.Thereportedadversereactionsareusuallymildandtransitory.

Sporadic,spontaneouscasesofhypercholesterolaemiahavebeenreported,butcausalityhasnotbeenestablished.

Patientswithdiabetesmellitus

Bloodglucosecontrolworsenedinpatientswithdiabetesmellitus.Frequencynotknown.

4.9Overdose

Signsandsymptomsofaccidentalorintentionaloverdosewithglucosaminemightincludeheadache,dizziness,

disorientation,arthralgia,nausea,vomiting,diarrhoeaorconstipation.

Incasesofoverdose,treatmentwithglucosamineshouldbediscontinuedandstandardsupportivemeasuresshouldbe

adoptedasrequired.

Inclinicaltrialsoneoffivehealthyyoungsubjectsexperiencedheadachefollowinginfusionofglucosamineupto30g.

Inaddition,onecaseofoverdosehasbeenreportedina12-yearoldfemalewhotookorally28gofglucosamine

SystemOrgan

Class Common(

1/100to<1/10) Uncommon(

1/1,000to

<1/100) Rare(

1/10,000to

<1/1000) Notknown

(cannotbe

estimatedfromthe

availabledata)

Immunesystem

disorders Allergicreaction

Eyedisorders Visualdisturbance

Nervoussystem

disorders Headache

Somnolence Dizziness

Gastrointestinal

disorders Nausea

Abdominal

pain

Dyspepsia

Diarrhoea

Constipation

Vomiting

Skinand

subcutaneous

tissuedisorders Erythema

Pruritus

Rash Angiodema

Urticaria

Hairloss

General

disordersand

administration

siteconditions Oedema/peripheral

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 26/07/2011 CRN 2055044 page number: 3

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Arthriaidtabletsareindicatedforthetreatmentofosteoarthritis.

Pharmacotherapeuticgroup:Otheranti-inflammatoryandanti-rheumaticagents,non-steroids.

ATCcode: M01AX05.

TheactiveingredientofArthriaidtablets,glucosaminesulfate,isanamino-monosaccharide.Itisanaturallyoccurring

compoundinallanimalsandhumanbeings.Glucosamineisaprecursorofthesynthesisofglucosaminoglycans

(GAGs)andhyaluronicacid,bothincludedinthecartilageaggrecan,andinothermacromoleculesincluding

gangliosides,glycolipidsandglycoproteins.

Anumberofin-vitroandanimalexperimentsillustratetheeffectsofglucosaminesulfate,butthemechanismofaction

relevanttohumanosteoarthritishasnotbeenfullyestablished.However,glucosamineisanormalconstituentofthe

polysaccharidechainsofcartilagematrixandsynovialfluidglucosaminoglycans.In-vitroandin-vivostudieshave

shownthatglucosaminesulfatestimulatesandthesynthesisofphysiologicalglycosaminoglycansandproteoglycansby

chondrocytesandofhyaluronicacidbysynoviocytes.

Glucosaminesulfatehasalsobeenshowntoinhibittheactivityofcartilage-destroyingenzymessuchascollagenase

andphospholipaseA2,aswellasthegenerationofothertissue-damagingsubstancessuchassuperoxideradicals,orthe

activityoflysosomalenzymes.Theseactivitiesmaycontributetothemildanti-inflammatoryeffectsobservedin-vivo

inexperimentalmodels,includingsometypesofexperimentalarthritis.UnlikeNSAIDs,glucosaminesulfatedoesnot

inhibitthesynthesisofprostaglandins.

Noeffectsonthecardiovascularandrespiratorysystems,ontheCNS,ortheautonomicnervoussystem,havebeen

showninsafetypharmacologystudies.

Efficacyofglucosaminehasbeendemonstratedinkneeosteoarthritis,andhasbeenpartlyreplicatedinosteoarthritisof

thespineandofotherjoints,includingthehip.Theefficacyofglucosaminesulfatehasnotbeenestablishedfor

osteoarthritisofthehand.

Evidenceofefficacyandsafetyhasbeenobtainedafterlong-term(threeyears)treatmentinkneeosteoarthritispatients.

AnalgesicsandNSAIDsmaybeusedconcomitantlywithglucosaminesulfate,eitherforrescueanalgesiaduring

possibleflaresofthedisease,orintheinitialperiodoftreatment,whenthesymptomaticeffectsofglucosaminesulfate

maybedelayedfor1-2weeks.Physicaltherapyprogramscanbeusedconcomitantlywithglucosaminesulfateinthe

overallmanagementofosteoarthritis.

5.2Pharmacokineticproperties

Thepharmacokineticpropertiesofglucosaminesulfatehavebeenstudiedintheratanddogusinguniformly 14

labelledglucosamine.

Followingintravenousadministration,radiolabelledglucosaminedisappearsrapidlyfrombloodandisincorporated

intovarioustissues,inparticulartheliver,kidneyandarticularcartilage.Inthelatter,theradioactivityfromlabelled

glucosamineremainsforaprolongedperiodoftime,withabiologicalhalflifeofabout70hours.About50%ofthe

administeredradioactivityisexhaledasCO

duringthe6daysfollowingtheadministration,30–40%isfoundinthe

urine,whereastheexcretionviathefaecesisonlyabout2%.

Afteroraladministration,radiolabelledglucosamineisrapidlyandalmostcompletelyabsorbed.Thesubsequent

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 26/07/2011 CRN 2055044 page number: 4

Apharmacokineticstudyinmanwithsingledosesofradiolabelledglucosaminebyi.v.,i.m.ororalrouteconfirmedthe

analogyofthepharmacokineticpatternofglucosaminewiththatfoundinanimals.

Theabsolutebioavailabilityinmanafterasingleoraldoseofradiolabelledglucosaminewas25%,duetothefirst-pass

effectintheliverinwhichmorethan70%ofglucosamineismetabolised.Thegastrointestinalabsorptioniscloseto

90%,sinceonly11%oftheadministeredradioactivityisexcretedinfaeces.

Studiesinmanwerealsoperformedafteri.v.ororaladministrationofunlabelledglucosamineandglucosaminewas

assayedbyionexchangechromatographyinbloodandurine.Thisassaymethodhasaquantitationlimitsufficientfor

soundpharmacokineticstudies.Nevertheless,theresultswereconsistentwiththoseobtainedwithradiolabelled

glucosamine.

5.3Preclinicalsafetydata

Thetoxicologicalstudiesperformedwithglucosaminesulfateindicatethelargesafetymarginofthedrug.

Thefollowingpreclinicalstudieswerecarriedout.Themaximumtesteddosesreportedherearethoseshowingnoor

minimaleffects,thesewerereversibleandtherewasnodetectabletargetorgantoxicity.

acutetoxicitystudiesinmiceandratsbyi.v.,i.m.andoralroute,withupto5000mg/kggivenbytheoralroute;

subchronictoxicitystudiesof4weeksintherabbitbythei.v.routeupto80mg/kg,intheratbytheoralrouteof

240mg/kg,andinthedogbythei.v.routefor13weeksupto300mg/kg;

chronictoxicitystudiesof52weeksintheratwithoraldosesupto2700mg/kg,andof26weeksinthedogwith

oraldosesofupto2149mg/kg;

embryotoxicitystudiesintheratandrabbitbytheoralrouteupto2500mg/kg,andfertilitystudiesintheratby

theoralrouteupto2149mg/kg;

mutagenicpotentialstudiesinvitrouptoconcentrationof5000µg/mlandinvivouptothedoseof1592mg/kg

intheratand7160mg/kginthemouse.

Thedosesusedrepresentaverylargemultipleofthedailydosecurrentlyusedinhumantherapy,whichisaround20-

25mg/kg.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Microcrystallinecellulose

Lactosemonohydrate

Pregelatinisedmaizestarch

Crospovidone

Stearicacid

Polyvinyl-alcoholparthydrolyzed

TitaniumdioxideE171

TalcE553b

LecithinsoyaE322

Macrogol3350

6.2Incompatibilities

Notapplicable.

6.3Shelflife

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 26/07/2011 CRN 2055044 page number: 5

6.4Specialprecautionsforstorage

Thisproductdoesnotrequireanyspecialtemperaturestorageconditions.

Storeintheoriginalpackageinordertoprotectfrommoisture

6.5Natureandcontentsofcontainer

CartonscontainingPVdCcoatedPVC/A1blisterstrips:

PackSize:7,10,14,20,21,28,30,56,60,84,90,168and180film-coatedtablets

CartonscontainingHDPEcontainersfittedwithatamper-evidentHDPEscrewcap.

PackSize:7,10,14,20,21,28,30,56,60,84,90,168and180film-coatedtablets

Notallpacksizesmaybemarketed

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Nospecialrequirements.

7MARKETINGAUTHORISATIONHOLDER

FMCPharmaLtd.

Unit622,NorthernExtension

Co.Waterford

8MARKETINGAUTHORISATIONNUMBER

PA1521/1/3

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:22 nd

July2011

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 26/07/2011 CRN 2055044 page number: 6